Pharmena S.A. (PHR) Price & Analysis

0 Followers

PHR Stock Chart & Stats

zł3.53

Market closed

zł3.53

Day’s Range― - ―

52-Week Rangezł2.50 - zł4.32

Previous CloseN/A

VolumeN/A

Average Volume (3M)2.66K

Market Cap

zł35.31M

Enterprise Valuezł35.24M

Total Cash (Recent Filing)zł6.79M

Total Debt (Recent Filing)zł340.00K

Price to Earnings (P/E)―

Beta0.30

Next Earnings

Sep 01, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.25

Shares Outstanding11,137,758

10 Day Avg. Volume1,473

30 Day Avg. Volume2,664

Financial Highlights & Ratios

PEG Ratio-0.08

Price to Book (P/B)3.00

Price to Sales (P/S)18.36

P/FCF Ratio-9.78

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

PHR FAQ

What was Pharmena S.A.’s price range in the past 12 months?

Pharmena S.A. lowest stock price was zł2.50 and its highest was zł4.32 in the past 12 months.

What is Pharmena S.A.’s market cap?

Pharmena S.A.’s market cap is zł35.31M.

When is Pharmena S.A.’s upcoming earnings report date?

Pharmena S.A.’s upcoming earnings report date is Sep 01, 2026 which is in 38 days.

How were Pharmena S.A.’s earnings last quarter?

Currently, no data Available

Is Pharmena S.A. overvalued?

According to Wall Street analysts Pharmena S.A.’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Pharmena S.A. pay dividends?

Pharmena S.A. pays a Annually dividend of zł2.36 which represents an annual dividend yield of N/A. See more information on Pharmena S.A. dividends here

What is Pharmena S.A.’s EPS estimate?

Pharmena S.A.’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Pharmena S.A. have?

Pharmena S.A. has 11,137,758 shares outstanding.

What happened to Pharmena S.A.’s price movement after its last earnings report?

Currently, no data Available

Which hedge fund is a major shareholder of Pharmena S.A.?

Currently, no hedge funds are holding shares in PL:PHR

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Pharmena S.A.

Pharmena S.A. engages in the sale of dietary supplements in Poland and internationally. It also develops 1-MNA (PHR-701 program), a medical device for use in difficult-to-heal wounds. In addition, the company is involved in research and development of therapeutic applications of 1 MNA as an anti-inflammatory and anti-fibrotic drug; and research and development at pulmonary fibrosis, respiratory tract infections, including viral infections, COVID-19, inflammatory diseases, metabolic diseases and other therapeutic applications. Pharmena S.A. was founded in 2002 and is based in Lódz, Poland. Pharmena S.A. operates as a subsidiary of Pelion S.A.